Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

NCT00274781 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: arsenic trioxide
DRUG: gemtuzumab ozogamicin

Sponsor

The Cleveland Clinic

Collaborators

[object Object]
[object Object]